Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
10.91
+0.16 (1.49%)
At close: Jun 27, 2025, 4:00 PM
10.92
+0.01 (0.09%)
After-hours: Jun 27, 2025, 4:04 PM EDT
Mesoblast Employees
Mesoblast had 73 employees as of June 30, 2024. The number of employees decreased by 10 or -12.05% compared to the previous year.
Employees
73
Change (1Y)
-10
Growth (1Y)
-12.05%
Revenue / Employee
$77,671
Profits / Employee
-$1,415,767
Market Cap
1.49B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
MESO News
- 16 days ago - Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD - GlobeNewsWire
- 6 weeks ago - FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil® - GlobeNewsWire
- 7 weeks ago - Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials - Seeking Alpha
- 2 months ago - Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025 - GlobeNewsWire
- 2 months ago - Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board - GlobeNewsWire
- 2 months ago - Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives - GlobeNewsWire
- 3 months ago - Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs - GlobeNewsWire
- 3 months ago - Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure - GlobeNewsWire